Mutations may underlie how the most aggressive lymphomas arise and resist therapies

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional preclinical study led by Weill Cornell Medicine investigators.

Related Keywords

Germany ,Gabriel Victora ,Michael Meyer Hermann ,Emily Henderson ,Helmholz Center ,Infection Research ,Rockefeller University ,Weill Cornell Medicine ,Gebroe Family Professor ,Edward Meyer Cancer Center ,Weill Cornell ,Industry Focus ,Coraline Mlynarczyk ,Lymphoma ,Utation ,Ntibody ,B Cell ,Dancer ,Fell ,Cell Division ,Gene ,Hematology ,Hodgkin Lymphoma ,Immune Response ,Medicine ,Non Hodgkin Lymphoma ,Ncology ,Reclinical ,Protein ,Protein Expression ,Research ,